Refine by
Autoimmune Condition Articles & Analysis: Older
19 news found
An equally effective oral alternative could change the treatment paradigm for a number of patient populations, including those with autoimmune diseases, cancer, and diabetes. “Therapeutic drug development has yielded a vast array of molecular entities, including peptides, antibodies and oligonucleotides. ...
The collaboration has already achieved two major milestones, with the first novel targets added to AstraZeneca’s portfolio for both CKD and IPF. SLE is a complex autoimmune condition that can affect multiple organ systems, and people often experience inadequate disease control, long-term organ damage and poor health-related quality of life. ...
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary Sjögren’s syndrome in Lupus, the importance of this protein across a spectrum of ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases, today announced the appointment of Amy Derosier as Vice President of Clinical Affairs. ...
Founded in 2007, SetPoint is dedicated to developing technologies to treat patients with chronic autoimmune diseases. The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “inflammatory reflex,” for rheumatoid arthritis (RA), Crohn’s disease and other chronic autoimmune diseases as a ...
"We hope to show that a simple intervention of activated B. infantis EVC001 starting in infancy could be life-altering in reducing the prevalence of this autoimmune condition, which would have far-reaching economic and societal benefits." T1D, also known as juvenile diabetes or autoimmune diabetes, can develop in the first years of life, and ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that the American Institute for Biological and Medical Engineering (AIMBE) has elected Murthy Simhambhatla, PhD, to the AIMBE College of Fellows for “outstanding contributions as a medical technology innovator and business leader, advancing ...
The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option. ...
New data on 14-3-3η (eta) enhances the detection rates of patients with secondary SS Serum 14-3-3η levels were found to be elevated in SLE patients with secondary SS compared to those with SLE without SS ROC analysis showed serum 14-3-3η levels as a predictor of SLE with secondary SS Levels of 14-3-3η significantly correlate with clinical and serological parameters (occular ...
About SetPoint Medical SetPoint Medical is a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases. SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic ...
About SetPoint Medical SetPoint Medical is a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases. SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in ...
Implications of the study The study’s findings represent a milestone in reducing intestinal inflammation during infancy, an occurrence linked to the development of allergic and autoimmune conditions later in life. This study also provides a further understanding of how the infant gut microbiome, the collection of microorganisms living in the gut, influences ...
The patients received stem cell therapy at the Okyanos clinic for conditions such as Parkinson’s disease, osteoarthritis, fibromyalgia and rheumatoid arthritis. In each case, Icellator X derived more than 100 million regenerative cells from the patients’ own adipose or fat tissue obtained through liposuction to treat their conditions. This higher ...
IBM is an autoimmune condition in which cytotoxic T cells attack muscle. Patients suffering from IBM have no reliably effective drug treatments currently available to them. This therapeutic will also be investigated for the treatment of PBC, an autoimmune condition in which pathogenic T cells attack bile ducts. While ...
Comella and her team were the first in the world to publish in-human results in the scientific literature about adipose-derived, autologous stem cells for the treatment of psoriasis — a chronic, painful skin condition that affects more than 7 million Americans every year. Dr. Comella is frequently published in the scientific literature on the practical application of ...